Show simple item record

dc.contributor.authorGoldman, Aaron
dc.contributor.authorMajumder, Biswanath
dc.contributor.authorDhawan, Andrew
dc.contributor.authorRavi, Sudharshan
dc.contributor.authorGoldman, David
dc.contributor.authorKohandel, Mohammad
dc.contributor.authorMajumder, Pradip K.
dc.contributor.authorSengupta, Shiladitya
dc.date.accessioned2015-04-30T13:52:01Z
dc.date.available2015-04-30T13:52:01Z
dc.date.issued2015-02
dc.date.submitted2014-07
dc.identifier.issn2041-1723
dc.identifier.urihttp://hdl.handle.net/1721.1/96854
dc.description.abstractUnderstanding the emerging models of adaptive resistance is key to overcoming cancer chemotherapy failure. Using human breast cancer explants, in vitro cell lines, mouse in vivo studies and mathematical modelling, here we show that exposure to a taxane induces phenotypic cell state transition towards a favoured transient ​CD44[superscript Hi]​CD24[superscript Hi] chemotherapy-tolerant state. This state is associated with a clustering of ​CD44 and ​CD24 in membrane lipid rafts, leading to the activation of Src Family Kinase (SFK)/​hemopoietic cell kinase (​Hck) and suppression of apoptosis. The use of pharmacological inhibitors of SFK/​Hck in combination with taxanes in a temporally constrained manner, where the kinase inhibitor is administered post taxane treatment, but not when co-administered, markedly sensitizes the chemotolerant cells to the chemotherapy. This approach of harnessing chemotherapy-induced phenotypic cell state transition for improving antitumour outcome could emerge as a translational strategy for the management of cancer.en_US
dc.description.sponsorshipUnited States. Dept. of Defense (Breast Cancer Research Program (U.S.) Collaborative Innovator Grant W81XWH-09-1-0700)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (RO1 1R01CA135242)en_US
dc.description.sponsorshipUnited States. Dept. of Defense (Breakthrough Award BC132168)en_US
dc.description.sponsorshipAmerican Lung Association (Innovation Award LCD-259932-N)en_US
dc.description.sponsorshipIndo-US Science and Technology Forum (Indo-US Joint Center Grant)en_US
dc.description.sponsorshipAmerican Cancer Society (Postdoctoral Fellowship 122854-PF-12-226-01-CDD)en_US
dc.language.isoen_US
dc.publisherNature Publishing Groupen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/ncomms7139en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.sourceNature Publishing Groupen_US
dc.titleTemporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transitionen_US
dc.typeArticleen_US
dc.identifier.citationGoldman, Aaron, Biswanath Majumder, Andrew Dhawan, Sudharshan Ravi, David Goldman, Mohammad Kohandel, Pradip K. Majumder, and Shiladitya Sengupta. “Temporally Sequenced Anticancer Drugs Overcome Adaptive Resistance by Targeting a Vulnerable Chemotherapy-Induced Phenotypic Transition.” Nature Communications 6 (February 11, 2015): 6139.en_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.mitauthorGoldman, Aaronen_US
dc.contributor.mitauthorSengupta, Shiladityaen_US
dc.relation.journalNature Communicationsen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsGoldman, Aaron; Majumder, Biswanath; Dhawan, Andrew; Ravi, Sudharshan; Goldman, David; Kohandel, Mohammad; Majumder, Pradip K.; Sengupta, Shiladityaen_US
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record